RARVYNLO
Live / Allowed — Fifth extension granted (statement of use) (as of 25 Sept 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 08 Mar 2023 filing date already counts against anyone who files later.
Record
- Serial number
- 97828784
- Mark type
- Word mark
- Filed
- 08 Mar 2023
- Published for opposition
- 02 Jan 2024
- Attorney of record
- Terrence J. McAllister
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral diseases and disorders, and for the treatment of pain
Owner
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, US
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, US
Prosecution history
- 25 Sept 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Sept 2026 — SOU EXTENSION 5 GRANTED
- 14 Aug 2026 — SOU EXTENSION 5 FILED
- 25 Sept 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 14 Aug 2026 — SOU TEAS EXTENSION RECEIVED
- 27 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Feb 2026 — SOU EXTENSION 4 GRANTED
- 26 Feb 2026 — SOU EXTENSION 4 FILED
- 26 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 26 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Jul 2025 — SOU EXTENSION 3 GRANTED
- 25 Jul 2025 — SOU EXTENSION 3 FILED
- 25 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 30 Jun 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 30 Jun 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED